Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus

Atherosclerosis

Volumn 212, Issue 1, 2010, Pages 217-222

  Schwartz, Eric A ^a   Koska, Juraj ^a   Mullin, Michael P ^a   Syoufi, Iyad ^a   Schwenke, Dawn C ^a   Reaven, Peter D ^a  

^a CARL T HAYDEN VA MEDICAL CENTER   (United States)

Author keywords

Apolipoprotein B 48; Apolipoprotein C III; Exenatide; High fat meal; NEFA; Remnant lipoproteins; Triglycerides

Indexed keywords

APOLIPOPROTEIN B48; APOLIPOPROTEIN C3; EXENDIN 4; FATTY ACID; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; PLACEBO; SODIUM CHLORIDE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CALORIC INTAKE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE TOLERANCE; HUMAN; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; LIPID BLOOD LEVEL; LIPID DIET; LIPOPROTEIN BLOOD LEVEL; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; WEIGHT REDUCTION;

ADULT; AGED; APOLIPOPROTEIN B-48; APOLIPOPROTEIN C-III; ARIZONA; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHOLESTEROL; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIETARY FATS; DOUBLE-BLIND METHOD; ENERGY INTAKE; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; PEPTIDES; POSTPRANDIAL PERIOD; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; VENOMS;

EID: 77956230708     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.05.028     Document Type: Article

References (32)

1. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
2. Haffner S.M., Stern M.P., Hazuda H.P., Mitchell B.D., Patterson J.K. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?. JAMA 1990, 263:2893-2898.
3. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
4. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. The Lancet 1999, 354:617-621.
5. American Diabetes Association Postprandial blood glucose. Diabetes Care 2001, 24:775-778.
6. Eberly L.E., Stamler J., Neaton J.D. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 2003, 163:1077-1083.
7. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298:309-316.
8. Zilversmit D.B. Atherogenesis: a postprandial phenomenon. Circulation 1979, 60:473-485.
9. Kawakami A., Osaka M., Tani M., Azuma H., Sacks F.M., Shimokado K., et al. Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation 2008, 118:731-742.
10. Goldberg I.J. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 1996, 37:693-707.
11. Karpe F., Steiner G., Uffelman K., Olivecrona T., Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994, 106:83-97.
12. Proctor S.D., Vine D.F., Mamo J.C. Arterial permeability and efflux of apolipoprotein B-containing lipoproteins assessed by in situ perfusion and three-dimensional quantitative confocal microscopy. Arterioscler Thromb Vasc Biol 2004, 24:2162-2167.
13. Haratz D., Stein O., Shwartz R., Berry E.M., Stein Y. Preferential metabolism by macrophages of conditioned rabbit hypercholesterolemic remnant lipoproteins. Biochim Biophys Acta 1988, 959:127-133.
14. Elsegood C.L., Pal S., Roach P.D., Mamo J.C. Binding and uptake of chylomicron remnants by primary and THP-1 human monocyte-derived macrophages: determination of binding proteins. Clin Sci (Lond) 2001, 101:111-119.
15. Speidel M.T., Booyse F.M., Abrams A., Moore M.A., Chung B.H. Lipolyzed hypertriglyceridemic serum and triglyceride-rich lipoprotein cause lipid accumulation in and are cytotoxic to cultured human endothelial cells. High density lipoproteins inhibit this cytotoxicity. Thromb Res 1990, 58:251-264.
16. Kolterman O.G., Buse J.B., Fineman M.S., Gaines E., Heintz S., Bicsak T.A., et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003, 88:3082-3089.
17. Klonoff D.C., Buse J.B., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008, 24:275-286.
18. Schwartz S.L., Ratner R.E., Kim D.D., Qu Y., Fechner L.L., Lenox S.M., et al. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. Clin Ther 2008, 30:858-867.
19. DeFronzo R.A., Okerson T., Viswanathan P., Guan X., Holcombe J.H., MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008, 24:2943-2952.
20. Koska J., Schwartz E.A., Mullin M.P., Schwenke D.C., Reaven PD Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Diabetes Care 2010, 33:1028-1030.
21. Meier J.J., Gethmann A., Gotze O., Gallwitz B., Holst J.J., Schmidt W.E., et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006, 49:452-458.
22. Cervera A., Wajcberg E., Sriwijitkamol A., Fernandez M., Zuo P., Triplitt C., et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 2008, 294:E846-E852.
23. Hsieh J., Baker C., Longuet C., Qin B., Drucker D.J., Adeli K. Glucagon-like peptide 1 (GLP-1) regulates postprandial lipid metabolism and attenuates postprandial lipids in an animal model of insulin resistance. ADA 69th scientific sessions on diabetes 2009, A245.
24. Qin X., Shen H., Liu M., Yang Q., Zheng S., Sabo M., et al. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol 2005, 288:G943-G949.
25. Vella A., Bock G., Giesler P.D., Burton D.B., Serra D.B., Saylan M.L., et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 2007, 56:1475-1480.
26. Matikainen N., Manttari S., Schweizer A., Ulvestad A., Mills D., Dunning B.E., et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006, 49:2049-2057.
27. Wang C.S., McConathy W.J., Kloer H.U., Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 1985, 75:384-390.
28. Clavey V., Lestavel-Delattre S., Copin C., Bard J.M., Fruchart J.C. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol 1995, 15:963-971.
29. Kawakami A., Osaka M., Aikawa M., Uematsu S., Akira S., Libby P., et al. Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation. Circ Res 2008, 103:1402-1409.
30. Scheffer P.G., Teerlink T., Dekker J.M., Bos G., Nijpels G., Diamant M., et al. Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: the Hoorn study. Clin Chem 2008, 54:1325-1330.
31. Pirro M., Mauriège P., Tchernof A., Cantin B., Dagenais G.R., Després J.-P., et al. Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Québec Cardiovascular Study. Atherosclerosis 2002, 160:377-384.
32. Tripathy D., Mohanty P., Dhindsa S., Syed T., Ghanim H., Aljada A., et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003, 52:2882-2887.